

Corrigendum to: Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population

Michele D. Spring,^{1,2} Jason C. Sousa,⁵ Qigui Li,⁵ Christian A. Darko,¹⁰ Meshell N. Morrison,⁶ Sean R. Marcisin,¹² Kristin T. Mills,¹³ Brittney M. Potter,⁵ Kristopher M. Paolino,¹⁴ Patrick S. Twomey,¹⁵ James E. Moon,⁷ Donna M. Tosh,¹⁶ Susan B. Cicatelli,⁶ Jeffrey W. Froude,¹⁷ Brandon S. Pybus,⁵ Thomas G. Oliver,³ William F. McCarthy,¹¹ Norman C. Waters,¹ Philip L. Smith,⁸ Gregory A. Reichard,⁵ and Jason W. Bennett^{4,9}

¹Department of Bacterial and Parasitic Diseases, US Army Medical Directorate of the Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; ²The Henry M. Jackson Foundation for the Advancement of Military Medicine; ³Clinical Pharmacology Division, ⁴Infectious Diseases Division, Department of Medicine, Uniformed Services University of the Health Sciences; ⁵Experimental Therapeutics Branch, ⁶Clinical Trials Center, ⁷Malaria Vaccine Branch, and ⁸Center for Enabling Capabilities, ⁹Bacterial Diseases Branch, Walter Reed Army Institute of Research, and ¹⁰General Dynamics Information Technology, Silver Spring, and ¹¹U. S. Army Medical Materiel Development Activity, Fort Detrick, Maryland; ¹²Food and Drug Administration, Boston, Massachusetts; ¹³Davita Medical Group, Colorado Springs, Colorado; ¹⁴Division of Infectious Disease, SUNY Upstate Medical University, Syracuse, New York; ¹⁵Licensing and Early Development—Oncology, Genentech, South San Francisco, California; ¹⁶Clinical Operations, Government and Public Health Solutions, ICON, Hinckley, Ohio; and ¹⁷Vaccines/Therapeutics Division, Defense Threat Reduction Agency, Fort Belvoir, Virginia

In “Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population” by Spring et al. [J Infect Dis 2019;220 (1 December); DOI: 10.1093/infdis/jiz386] the panels in Figure 2 are mislabeled in the figure legend. The correct Figure 2 legend should read: Pharmacokinetic profiles in plasma (A and C) and urine

(B and D, dotted lines) specimens from volunteers with the normal metabolizer (NM) phenotype (circles; n = 8), the intermediate metabolizer (IM) phenotype (triangles; n = 20), and the poor metabolizer (PM) phenotype (squares; n = 16) for primaquine (PQ; A and B) and carboxyprimaquine (cPQ; C and D) at scheduled time points after administration of 30 mg of PQ orally. Data are median values. The authors regret the error.

DOI: 10.1093/infdis/jiz599

Corrigendum to: A Systematic Review of Clinical Practice Guidelines for the Diagnosis and Management of Bronchiolitis

Amir Kirolos,^{1,⊕} Sara Manti,⁶ Rachel Blacow,¹ Gabriel Tse,¹ Thomas Wilson,¹ Martin Lister,⁴ Steve Cunningham,^{2,3} Alasdair Campbell,⁵ Harish Nair,^{1,⊕} Rachel M Reeves,¹ Ricardo M Fernandes,⁷ and Harry Campbell,^{1,⊕} for the RESCEU Investigators

¹Usher Institute of Population Health Sciences and Informatics, ²Department of Child Life and Health, and ³Centre for Inflammation Research, University of Edinburgh, and ⁴Royal Hospital for Sick Children, Edinburgh, and ⁵Alder Hey Children’s Hospital, Liverpool, United Kingdom; ⁶Department of Pediatrics, University of Messina, Sicily, Italy; and ⁷Clinical Pharmacology and Therapeutics, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon

In “A Systematic Review of Clinical Practice Guidelines for the Diagnosis and Management of Bronchiolitis” by Kirolos et al. [J Infect Dis 2019. doi:10.1093/infdis/jiz240], Table 1 and Figure

1 have been moved from supplementary material to the main body of the article for clarity.

The authors regret the error.

DOI: 10.1093/infdis/jiz600

The Journal of Infectious Diseases® 2020;221:1204

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com